Science

Matthew Oberley: Validating HRD-Status Testing to Predict PARP Inhibitor Benefit

Matthew Oberley/LinkedIn

May 12, 2025, 09:01

Matthew Oberley: Validating HRD-Status Testing to Predict PARP Inhibitor Benefit

Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post on LinkedIn:

“Test validations usually require comparing the new test directly to a gold standard test using the same specimen. This is exactly what we did with our currently available clinically validated HRD-status testing algorithm which measures genomic scarring across the human genome from whole exome sequencing in association with evaluation for BRCA1/2 alterations. The test indication is to identify patients that may benefit from PARP inhibitors.

What is really fun for me working at Caris, is that we have treatment and clinical outcomes data to layer into clinical validations of our tests. In this case, we show our HRD-status testing predicts benefit for patients treated with PARP inhibitors as expected; we recently worked with our Precision Oncology Alliance colleagues to publish this novel approach. Congrats to Elizabeth Evans, Jhalak Dholakia, Jim Abraham, PhD, Andrew Hinton, Jian Zhang, Joanne Xiu, Ph. D., Todd Maney, Premal Thaker, Thomas Herzog, David Spetzler, and Rebecca Arend!”

Title: Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors

Authors: Elizabeth Evans, Jhalak Dholakia, Jim Abraham, Andrew Hinton, Jian Zhang, Joanne Xiu, Todd Maney, Matt Oberley, Premal Thacker, Thomas J. Herzog, David Spetzler, Rebecca C. Arend

Read the full article in Gynecologic Oncology.

Matthew Oberley: Validating HRD-Status Testing to Predict PARP Inhibitor Benefit